Gilead Sciences has commenced 2026 with a demonstrably strong first quarter, reporting significant revenue growth primarily fueled by its leading HIV treatment and prevention portfolio. The biopharmaceutical giant announced total revenue of $7 billion for Q1 2026, representing a healthy 4% increase year-on-year and surpassing analyst expectations. This robust performance underscores the sustained market dominance of its flagship HIV medications and the promising trajectory of newer preventative therapies.
The company’s total product sales reached $6.9 billion during the quarter, with its HIV segment emerging as a powerhouse, contributing a remarkable $5 billion. This segment alone experienced a substantial 10% year-on-year growth, highlighting Gilead’s continued leadership in addressing the global HIV epidemic.
Biktarvy Continues its Reign as the Top HIV Treatment
At the forefront of Gilead’s HIV success is Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a once-daily, three-drug regimen. In Q1 2026, Biktarvy generated an impressive $3.36 billion in global sales, a notable increase from the $3.15 billion recorded in the corresponding period of 2025. This performance solidifies Biktarvy’s position as the best-selling HIV medicine worldwide, capturing over half of the market share within the indication. Its sustained popularity among healthcare providers and patients is attributed to its well-established efficacy, favorable safety profile, and convenient single-tablet regimen.
The enduring success of Biktarvy is a testament to Gilead’s long-standing commitment to HIV research and development. Since its initial approval by the U.S. Food and Drug Administration (FDA) in February 2018, Biktarvy has become a cornerstone of HIV treatment guidelines, particularly for initial therapy and for patients switching from other regimens due to improved tolerability or efficacy. Its comprehensive clinical trial data, demonstrating high rates of viral suppression and a low incidence of drug resistance, has fostered deep trust within the medical community.
Evolving HIV Treatment Landscape and Emerging Competition
While Biktarvy continues to dominate, the HIV treatment landscape is dynamic, with new therapeutic options emerging. Notably, MSD (known as Merck & Co. in the United States and Canada) received U.S. regulatory approval in April 2026 for its two-drug regimen, Idvynso (doravirine/islatravir). This INSTI-reliant therapy represents a shift towards simpler, potentially more tolerable treatment options for individuals living with HIV.
Anaelle Tannen, a senior analyst at GlobalData, previously commented on this evolving trend, stating, "The approval of Idvynso reflects a broader movement in HIV treatment away from traditional three-drug combinations towards more streamlined approaches. This often translates to improved patient adherence and potentially fewer side effects." However, Tannen also offered a nuanced perspective on Idvynso’s immediate impact on Biktarvy’s market leadership. "Despite the introduction of new competitors like Idvynso, it is unlikely to displace Biktarvy as a frontline option in the near term. Physicians are deeply familiar with Biktarvy’s established efficacy and safety profile, built over years of real-world use and extensive clinical experience." This physician confidence, coupled with extensive patient familiarity, provides a significant barrier to entry for newer regimens in the first-line setting.
PrEP Portfolio Shines with Descovy’s Growth and Yeztugo’s Ascending Launch
Beyond treatment, Gilead’s preventative HIV medications, known as pre-exposure prophylaxis (PrEP), have also demonstrated remarkable performance in Q1 2026. Descovy (emtricitabine 200mg/tenofovir alafenamide 25mg) generated $807 million in sales, marking a substantial 38% increase from the $586 million reported in 2025. This growth significantly surpassed consensus estimates for the quarter, indicating strong demand for this key PrEP option.
The most significant development in Gilead’s prevention portfolio, however, is the continued launch of Yeztugo (lenacapavir), the company’s novel, twice-yearly injectable PrEP therapy. Yeztugo made its market debut following its successful demonstration of preventing 100% of HIV cases in a pivotal late-stage clinical trial involving women. Since receiving U.S. FDA approval in June 2025, Yeztugo has experienced an impressive early market uptake, generating $166 million in sales during the first quarter of 2026.
The growing acceptance and utilization of Yeztugo come at a critical juncture in global HIV prevention efforts. Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), has previously lauded Yeztugo as a "powerful tool" in the absence of a widely available HIV vaccine. The twice-yearly administration offers a significant advantage in terms of adherence and convenience, potentially reaching populations who may struggle with daily oral medications.
Gilead is optimistic about Yeztugo’s future, forecasting that it will achieve blockbuster status (annual sales exceeding $1 billion) by the end of 2026. Analysts at Jefferies echoed this sentiment in an 8 May research note, deeming the target "doable." They further suggested that the PrEP market, in general, may prove to be "larger than expected," with Gilead strategically positioned to capitalize on and expand this market. The company’s dual approach, offering both daily oral options like Descovy and long-acting injectables like Yeztugo, allows it to cater to a wider range of patient preferences and needs, a key factor in maximizing market penetration.
Anito-cel: A Glimpse into Gilead’s Future Oncology Pipeline
While Gilead’s HIV franchise continues to be the primary engine of its growth, investors are keenly observing the company’s burgeoning oncology pipeline, particularly with the anticipated launch of anitocabtagene autoleucel (anito-cel). This BCMA-directed, ex vivo chimeric antigen receptor T-cell (CAR-T) therapy is being developed for relapsed or refractory multiple myeloma (R/R MM) and was acquired through Gilead’s substantial $7.8 billion takeover of Arcellx.
The FDA is currently reviewing anito-cel, with a decision expected in December 2027. Gilead anticipates that anito-cel will begin generating revenue in early 2027, positioning it as a significant future contributor to the company’s financial performance.
GlobalData analysts have identified anito-cel as a potential "strong best-in-class contender" within the R/R MM indication. This assessment is based on its demonstrated high complete response rates in clinical trials, a favorable safety profile, and the potential for community-based delivery, which could significantly improve patient access and reduce the burden on specialized treatment centers.
Jefferies analysts have also expressed a positive outlook on anito-cel, highlighting its "differentiated safety" profile compared to Johnson & Johnson’s Carvykti (ciltacabtagene autoleucel), a direct competitor in the BCMA-targeted CAR-T space. This comparative advantage in safety could translate into broader physician adoption and improved patient outcomes, further bolstering anito-cel’s market potential. The successful integration of Arcellx’s innovative CAR-T platform signifies Gilead’s strategic intent to diversify its revenue streams and establish a strong presence in the competitive and rapidly evolving field of oncology.
Broader Implications and Future Outlook
Gilead’s robust Q1 2026 performance sets a positive tone for the remainder of the year. The company’s ability to sustain high growth in its established HIV portfolio, coupled with the promising early success of its new PrEP therapy, Yeztugo, demonstrates its strategic agility and market leadership. The anticipated launch of anito-cel in the oncology space further signals Gilead’s commitment to innovation and expansion into new therapeutic areas with significant unmet medical needs.
The company’s financial strength, derived from its diversified product offerings, provides a solid foundation for continued investment in research and development, as well as strategic acquisitions. As Gilead navigates the evolving healthcare landscape, its focus on developing and delivering innovative treatments for life-threatening diseases, from HIV to multiple myeloma, positions it for sustained growth and impact in the years to come. The market will continue to closely monitor the progression of anito-cel through its regulatory review and the ongoing expansion of Yeztugo’s market penetration, both of which are poised to be key drivers of Gilead’s future success.
Leave a Reply